Arthur Charles Regan
|
None
|
None
|
Dr. Daniel C. Robeson
|
None
|
None
|
The Nominees do not currently oversee any portfolios in MSP's Fund Complex. As of the close of business on June 22, 2017, neither of the Nominees owned any securities of MSP. Each of our Nominees, as a member of a "group" for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), may be deemed to beneficially own the Shares owned in the aggregate by the other members of the group. Each of our Nominees disclaims beneficial ownership of such Shares, except to the extent of his pecuniary interest therein. For information regarding purchases and sales of securities of MSP during the past two (2) years by the Participants (as defined below), see
Appendix A hereto (which is incorporated herein by reference).
None of the Nominees, nor their affiliates or any other related persons, has, during the past 5 years, held any position, including as an officer, employee, Trustee or general partner, with (i) the Fund, (ii) any investment company, or any person that would be an investment company but for the exclusions provided by Sections 3(c)(1) and (c)(7) of the Investment Company Act of 1940 (the "Investment Company Act"), having the same investment adviser, principal underwriter or Sponsoring Insurance Company (as such item is defined in the Investment Company Act) or under the control of such investment adviser, principal underwriter or Sponsoring Insurance Company, as the Fund, (iii) the Fund's investment adviser, principal underwriter or Sponsoring Insurance Company and (iv) any person, directly or indirectly controlling, controlled by, or under common control of the Fund's investment adviser, principal underwriter, or Sponsoring Insurance Company.
Since the beginning of the Fund's last two completed fiscal years, no officer of an investment adviser, principal underwriter, or Sponsoring Insurance Company of the Fund, or of a person directly or indirectly controlling, controlled by, or under common control thereby, serves, or has served, on the board of directors of a company of which any of the Nominees is an officer.
Since the beginning of the Fund's last two completed fiscal years, none of the Nominees nor any of their associates was a party to any transaction, or series of similar transactions or is a party to any currently proposed transaction, or series of similar transactions, in which the amount involved exceeded or is to exceed $120,000, to which (i) the Fund, (ii) any of its officers, (iii) any investment fund, or officer thereof, or any person, or officer thereof, that would be an investment fund but for the exclusions provided by Sections 3(c)(1) and (c)(7) of the Investment Company Act, having the same investment adviser, principal underwriter or Sponsoring Insurance Company or under the control of such investment adviser, principal underwriter or Sponsoring Insurance Company, as the Fund, (iv) the Fund's investment adviser, principal underwriter or Sponsoring Insurance Company, or officer thereof, or (v) any person, or officer thereof, directly or indirectly controlling, controlled by, or under common control of the Fund's investment adviser, principal underwriter, or Sponsoring Insurance Company, was or is to be a party.
None of the Nominees nor any of their Immediate Family Members (as such term is defined in the Investment Company Act) has or has had any direct or indirect interest, the value of which exceeded or is to exceed $120,000, during the past five years, in (i) the Fund's investment adviser, principal underwriter or Sponsoring Insurance Company; or (ii) any person (other than a registered investment company) directly or indirectly controlling, controlled by, or under common control with the Fund's investment adviser, principal underwriter, or Sponsoring Insurance Company.
None of the Nominees nor any of their Immediate Family Members owns beneficially or of record any class of securities in (i) the Fund's investment adviser, principal underwriter or Sponsoring Insurance Company; or (ii) any person (other than a registered investment company) directly or indirectly controlling, controlled by, or under common control with the Fund's investment adviser, principal underwriter, or Sponsoring Insurance Company.
None of the Nominees or any of their Immediate Family Members has, or has had since the beginning of the Fund's last two completed fiscal years, or has currently proposed, any direct or indirect relationship, in which the amount involved exceeds $120,000, with any of the persons specified in paragraphs (b)(8)(i) through (b)(8)(viii) of Item 22 of Schedule 14A.
Mr. Regan's firm, Regan & Associates, Inc. has been retained by Karpus to assist in its proxy solicitation efforts and consultative roles to aid Karpus in achieving its objectives of succeeding on both Proposals and to elect what it deems is independent representation on the Fund's Board.
On April 28, 2017, the Nominees entered into a Joint Filing and Solicitation Agreement (the "Joint Filing and Solicitation Agreement") with the other members of the Karpus Group in which, among other things, (a) the Karpus Group agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of MSP and (b) the Karpus Group agreed to form the group for the purpose of soliciting proxies or written consents for the election of the Nominees at the Annual Meeting and for the Proposals and for the purpose of taking all other actions incidental to the foregoing.
Other than as stated herein, there are no arrangements or understandings among members of the Karpus Group and any of our Nominees or any other person or persons pursuant to which the nomination of our Nominees described herein is to be made, other than the consent by each Nominee to be named in this Proxy Statement and to serve as a Trustee of MSP, if elected as such at the Annual Meeting. None of our Nominees is a party adverse to MSP, or any of its subsidiaries, or has a material interest adverse to MSP, or any of its subsidiaries, in any material pending legal proceeding.
Karpus believes that each Nominee presently is, and if elected as a Trustee of the Fund, will be, an "independent director" within the meaning of (i) applicable New York Stock Exchange listing standards applicable to board composition, including Rule 303A.02, and (ii) Section 301 of the Sarbanes-Oxley Act of 2002, as amended. No Nominee is a member of the Fund's compensation, nominating or audit committees that is not independent under any such committee's applicable independence standards.
We do not expect that any of our Nominees will be unable to stand for election, but, in the event that any Nominee is unable to serve or will not serve, the Shares represented by the enclosed
GREEN proxy card will be voted for substitute nominee(s), to the extent this is not prohibited under the Fund's First Amended and Restated By-Laws (the "Bylaws") and applicable law. In addition, we reserve the right to nominate substitute person(s) if MSP makes or announces any changes to the Bylaws or takes or announces any other action that has, or if consummated would have, the effect of disqualifying any Nominee, to the extent this is not prohibited under the Bylaws and applicable law. In any such case, the Shares represented by the enclosed
GREEN proxy card will be voted for such substitute nominee(s). We reserve the right to nominate additional person(s), to the extent this is not prohibited under the Bylaws and applicable law, if MSP increases the size of the Board above its existing size or increases the number of Trustees whose terms expire at the Annual Meeting. Additional nominations made pursuant to the preceding sentence are without prejudice to the position of Karpus that any attempt to increase the size of the current Board or to change the classifications of the Board would constitute an unlawful manipulation of MSP's corporate machinery.
The information provided above has been furnished to Karpus by the Nominees.
ADDITIONAL INFORMATION CONCERNING THE PARTICIPANTS
Karpus Management, Inc., d/b/a Karpus Investment Management ("Karpus"), Karpus Investment Management Profit Sharing Plan Fund C - Growth Common Stock Fund ("Karpus Plan"), George W. Karpus (together with Karpus and the Karpus Plan, the "Karpus Group"), Arthur Charles Regan, and Dr. Daniel C. Robeson (each a "Participant" and collectively, the "Participants") are deemed to be the participants in this proxy solicitation.
Karpus was founded in 1986. George W. Karpus' principal business and occupation is as the President, CEO and Controlling Stockholder. Karpus' principal business and occupation is an independent registered Investment Adviser and provides investment management for individuals, pension plans, profit sharing plans, corporations, endowments, trusts and others. Karpus Plan's principal business and occupation is investing in securities.
Karpus', Karpus Plan's and Mr. Karpus' principal business address is: 183 Sully's Trail, Pittsford, New York 14534 (a suburb of Rochester). The principal business and occupation and principal business addresses of the Nominees is set forth elsewhere in this Proxy Statement.
As of the date hereof, the following held shares of MSP common shares: (1) Karpus, through its accounts, represents beneficial ownership of 1,399,348 shares and (2) Mr. Karpus, as the President and CEO of Karpus Management, may be deemed the beneficial owner of 16,450 shares, consisting of (i) 3,150 shares owned in the aggregate by The Karpus Family Foundation, Inc ("Karpus Foundation") and (ii) 13,300 shares held by Karpus Plan. Neither Mr. Regan nor Dr. Robeson own any shares of MSP. Each Participant disclaims beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein. The Shares beneficially owned by each of Karpus, Karpus Plan, Karpus Foundation and Mr. Karpus were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). Please see
Appendix A for a list of the Participants' last two years' transactions in MSP.
Karpus' beneficial ownership of 1,399,348 common shares of MSP is approximately 24.1% of MSP's outstanding common shares. Such calculation is based on 5,798,291 common shares outstanding, as indicated on MSP's Annual Report, filed with the U.S. Securities and Exchange Commission on March 1, 2017, as of December 31, 2016.
Since it filed its Schedule 13D in February 2016, Karpus has spoken with Fund management and counsel for MCN and MSP on multiple occasions regarding its concerns. Karpus has also submitted Trustee Nominees, a proposal to terminate the Adviser of both Funds, as well as a non-binding shareholder proposal for shareholders' consideration at MSP's and MCN's 2017 Annual Meetings (or any postponements or adjournments thereof).
On April 28, 2017, the Nominees entered into a Joint Filing and Solicitation Agreement (the "Joint Filing and Solicitation Agreement") with the other members of the Karpus Group in which, among other things, (a) the Karpus Group agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of MSP and (b) the Karpus Group agreed to form the group for the purpose of soliciting proxies or written consents for the election of the Nominees at the Annual Meeting and for the Proposals and for the purpose of taking all other actions incidental to the foregoing.
Except as set forth in this Proxy Statement (including the Appendices hereto), (i) during the past 10 years, no Participant has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no Participant directly or indirectly beneficially owns any securities of the Fund; (iii) no Participant owns any securities of the Fund which are owned of record but not beneficially; (iv) no Participant has purchased or sold any securities of the Fund during the past two years; (v) no part of the purchase price or market value of the securities of the Fund owned by any Participant is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities; (vi) no Participant is, or within the past year was, a party to any contract, arrangements or understandings with any person with respect to any securities of the Fund, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; (vii) no associate of any Participant owns beneficially, directly or indirectly, any securities of the Fund; (viii) no Participant owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Fund; (ix) no Participant or any of his associates was a party to any transaction, or series of similar transactions, since the beginning of the Fund's last fiscal year, or is a party to any currently proposed transaction, or series of similar transactions, to which the Fund or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000; (x) no Participant or any of his associates has any arrangement or understanding with any person with respect to any future employment by the Fund or its affiliates, or with respect to any future transactions to which the Fund or any of its affiliates will or may be a party; (xi) no Participant has a substantial interest, direct or indirect, by securities holdings or otherwise in any matter to be acted on at the Annual Meeting; (xii) no Participant holds any positions or offices with the Fund; (xiii) no Participant has a family relationship with any director, executive officer, or person nominated or chosen by the Fund to become a director or executive officer and (xiv) no companies or organizations, with which any of the Participants has been employed in the past five years, is a parent, subsidiary or other affiliate of the Fund. Except as set forth in this Proxy Statement, there are no material proceedings to which any Participant or any of his associates is a party adverse to the Fund or any of its subsidiaries or has a material interest adverse to the Fund or any of its subsidiaries. With respect to each of the Participants, except as set forth in this Proxy Statement, none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the Exchange Act occurred during the past 10 years.
Except as set forth in this Proxy Statement there are no arrangements or understandings between any member of the Karpus Group and the Nominees or any other Participant in this solicitation.
ADDITIONAL INFORMATION
Karpus has omitted from this Proxy Statement certain disclosures that are included in the Fund's proxy statement. Shareholders should refer to the Fund's proxy statement in order to review these disclosures.
The information concerning the Fund contained in this Proxy Statement has been taken from, or is based upon, publicly available information. Although Karpus does not have any information that would indicate that any information contained in this Proxy Statement concerning the Fund is inaccurate or incomplete, Karpus does not take any responsibility for the accuracy or completeness of such information.
IMPORTANT
TELL YOUR BOARD WHAT YOU THINK! Your vote is extremely important. No matter how many shares you own, please give Karpus your proxy
FOR ALL KARPUS NOMINEES, FOR PROPOSAL 2 and FOR PROPOSAL 3 by voting your shares by telephone or Internet as described on the enclosed
GREEN proxy card or by signing and dating the enclosed
GREEN proxy card, and returning it in the postage-paid envelope provided.
If any of your shares are held in the name of a brokerage firm, bank, bank nominee or other institution, only it can vote such shares and only upon receipt of your specific instructions. Accordingly, please contact the person responsible for your account and instruct that person to execute the GREEN proxy card. In addition, if you hold your shares in a brokerage or bank account, your broker or bank may allow you to provide your voting instructions by telephone or Internet. Please consult the materials you receive from your broker or bank prior to authorizing a proxy by telephone or Internet. Karpus urges you to confirm in writing your instructions to Karpus in care of Regan & Associates, Inc. at the address provided below so that Karpus will be aware of all instructions given and can attempt to ensure that such instructions are followed.
Questions, or requests for additional copies of this Proxy Statement, should be directed to:
Regan & Associates, Inc.
505 Eighth Avenue, Suite 800
New York, New York 10018
(800) 737-3426
-or-
Brett D. Gardner, Sr. Corporate Governance Analyst
Travis M. Gallton, CFA, Sr. Equity Portfolio Manager
Karpus Management, Inc., d/b/a Karpus Investment Management
183 Sully's Trail
Pittsford, New York 14534
(585) 586-4680
KARPUS INVESTMENT MANAGEMENT
July 10, 2017
THIS SOLICITATION IS BEING MADE BY KARPUS AND NOT ON BEHALF OF THE BOARD OF TRUSTEES OR MANAGEMENT OF MSP. KARPUS IS NOT AWARE OF ANY OTHER MATTERS TO BE BROUGHT BEFORE THE ANNUAL MEETING. SHOULD OTHER MATTERS, WHICH KARPUS IS NOT AWARE OF WITHIN A REASONABLE TIME BEFORE THIS SOLICITATION, BE BROUGHT BEFORE THE ANNUAL MEETING, THE PERSONS NAMED AS PROXIES IN THE ENCLOSED
GREEN PROXY CARD WILL VOTE ON SUCH MATTERS IN THEIR DISCRETION.
KARPUS URGES YOU TO VOTE IN FAVOR OF THE ELECTION OF KARPUS'S NOMINEES, EITHER BY TELEPHONE OR BY INTERNET AS DESCRIBED IN THE ENCLOSED
GREEN PROXY CARD OR BY SIGNING, DATING AND RETURNING THE ENCLOSED
GREEN PROXY CARD TODAY.
APPENDIX A
Transactions in Securities of the Fund During the Past Two Years
Karpus Management, Inc., d/b/a Karpus Investment Management (through the accounts)
Shares of Common Stock Date of
Purchased/(Sold) Purchase/Sale
6,094 7/10/2015
66,520 7/13/2015
3,857 7/14/2015
2,411 7/15/2015
3,866 7/16/2015
5,323 7/17/2015
3,599 7/20/2015
6,000 7/21/2015
3,000 7/22/2015
891 7/23/2015
6,318 7/27/2015
7,360 7/28/2015
7,000 7/29/2015
1,100 7/30/2015
7,300 7/31/2015
379 8/3/2015
1,518 8/4/2015
6,538 8/5/2015
4,289 8/6/2015
2,999 8/7/2015
10,955 8/10/2015
1,300 8/12/2015
2,000 8/13/2015
2,000 8/14/2015
2,000 8/17/2015
1,250 8/21/2015
6,707 8/24/2015
2,300 8/26/2015
100 8/27/2015
(450) 8/28/2015
159 9/1/2015
1,950 9/2/2015
3,050 9/3/2015
3,043 9/10/2015
4,140 9/11/2015
1,905 9/14/2015
17,000 9/15/2015
14,225 9/16/2015
906 9/17/2015
(850) 9/21/2015
2,370 9/23/2015
6,732 9/30/2015
2,517 10/5/2015
9,231 10/7/2015
28,141 10/8/2015
2,000 10/9/2015
874 10/12/2015
800 10/13/2015
19,643 10/14/2015
16,107 10/15/2015
10,700 10/16/2015
8,459 10/19/2015
20,311 10/20/2015
9,920 10/21/2015
5,070 10/22/2015
275 10/23/2015
13,007 10/27/2015
10,607 10/28/2015
1,032 10/29/2015
5,450 11/4/2015
1,100 11/5/2015
1,050 11/6/2015
1,946 11/10/2015
14,296 11/11/2015
5,500 11/12/2015
853 11/13/2015
1,500 11/16/2015
8,293 11/17/2015
197 11/18/2015
(500) 12/14/2015
200 1/13/2016
10,200 1/14/2016
5,264 1/15/2016
12,517 1/19/2016
29,800 1/20/2016
30,245 1/21/2016
7,329 1/22/2016
38,889 1/25/2016
19,613 1/26/2016
9,300 1/27/2016
900 1/28/2016
10,735 1/29/2016
800 2/1/2016
400 2/2/2016
9,000 2/8/2016
(450) 2/10/2016
9,058 2/12/2016
6,106 2/16/2016
730 2/17/2016
2,620 2/18/2016
5,994 2/19/2016
16,130 2/22/2016
500 2/23/2016
2,527 2/26/2016
3,865 3/1/2016
(650) 3/2/2016
500 3/4/2016
600 3/18/2016
5,914 3/21/2016
7,186 3/22/2016
300 3/23/2016
7,589 3/24/2016
2,000 3/28/2016
2,600 3/29/2016
640 4/4/2016
102 4/6/2016
2,000 4/7/2016
1,965 4/8/2016
878 4/11/2016
6,100 4/12/2016
(300) 4/18/2016
2,232 4/19/2016
3,718 4/20/2016
6,092 4/21/2016
2,689 4/22/2016
3,335 4/25/2016
1,985 4/26/2016
4,382 4/27/2016
6,028 4/28/2016
3,235 4/29/2016
8,700 5/2/2016
12,800 5/4/2016
4,145 5/5/2016
1,430 5/6/2016
2,200 5/10/2016
2,975 5/11/2016
5,000 5/12/2016
2,602 5/13/2016
3,000 5/16/2016
1,142 5/17/2016
1,300 5/18/2016
10,500 5/19/2016
820 5/20/2016
900 5/23/2016
(1) 6/2/2016
(300) 6/16/2016
(500) 7/1/2016
(750) 7/8/2016
(450) 8/10/2016
100 8/29/2016
250 8/30/2016
100 8/31/2016
(1,180) 9/1/2016
200 9/14/2016
1,630 9/15/2016
20,610 9/16/2016
3,804 9/19/2016
615 9/20/2016
450 9/21/2016
200 9/23/2016
6,978 9/26/2016
79,364 9/27/2016
68,378 9/28/2016
1,680 9/29/2016
700 9/30/2016
5,000 10/4/2016
100 10/5/2016
7,300 10/6/2016
800 10/7/2016
645 10/11/2016
1,275 10/12/2016
5,700 10/13/2016
9,200 10/14/2016
3,780 10/17/2016
555 10/18/2016
1,200 10/19/2016
8,285 10/20/2016
1,250 10/25/2016
1,150 10/26/2016
100 10/27/2016
1,000 10/31/2016
2,592 11/2/2016
2,725 11/3/2016
1,370 11/4/2016
570 11/7/2016
3,600 11/8/2016
1,400 11/9/2016
8,400 11/10/2016
405 11/11/2016
1,600 11/15/2016
105 11/16/2016
6,801 11/17/2016
1,252 11/21/2016
6,284 11/28/2016
250 11/29/2016
466 11/30/2016
75 12/1/2016
1,680 12/2/2016
157,990 12/5/2016
158,750 12/6/2016
374 12/8/2016
(1,954) 12/14/2016
3,614 12/16/2016
570 12/20/2016
925 12/21/2016
(560) 12/23/2016
(300) 2/1/2017
(880) 2/6/2017
(450) 2/8/2017
3,100 2/23/2017
5,689 2/24/2017
943 2/28/2017
975 3/1/2017
9,045 3/7/2017
4,494 3/8/2017
(1,304) 3/17/2017
(3,740) 3/20/2017
(2,256) 3/21/2017
3,000 3/23/2017
7,759 4/6/2017
(1,235) 4/19/2017
(1,145) 4/20/2017
25,000 5/3/2017
200 5/5/2017
(990) 6/6/2017
1,900 6/7/2017
The Karpus Family Foundation, Inc.
(George W. Karpus)
Shares of Common Stock Date of
Purchased/(Sold) Purchase/Sale
3,150 7/13/2015
Karpus Investment Management Profit Sharing Plan Fund C - Growth Common Stock Fund
(George W. Karpus)
Shares of Common Stock Date of
Purchased/(Sold) Purchase/Sale
8,381 1/19/2016
4,919 1/21/2016
GREEN PROXY CARD
MADISON STRATEGIC SECTOR PREMIUM FUND (MSP)
2017 ANNUAL MEETING OF SHAREHOLDERS
THIS PROXY IS SOLICITED ON BEHALF OF KARPUS MANAGEMENT, INC.,
D/B/A KARPUS INVESTMENT MANAGEMENT ("KARPUS")
THE BOARD OF TRUSTEES OF MADISON STRATEGIC SECTOR PREMIUM FUND
IS NOT SOLICITING THIS PROXY
P R O X Y
The undersigned appoints Brett D. Gardner, Travis M. Gallton, CFA, or Arthur Charles Regan as the undersigned's attorneys and agents with full powers of substitution to vote all shares of common stock of the Madison Strategic Sector Premium Fund (the "Fund" or "MSP") which the undersigned would be entitled to vote if personally present at the Annual Meeting of Shareholders of the Fund scheduled to be held at 550 Science Drive, Madison, Wisconsin 53711 at 10:00 a.m., Central Time, on Tuesday, August 22, 2017, including any adjournments, postponements, or delays thereof or any meeting which may be called in lieu thereof (the "Annual Meeting").
The undersigned hereby revokes any other proxy or proxies heretofore given to vote or act with respect to the shares of common stock of the Fund held by the undersigned, and hereby ratifies and confirms all actions the herein named attorneys and proxies, their substitutes, or any of them may lawfully take by virtue hereof. If properly executed, this Proxy will be voted as directed and in the discretion of such attorneys and proxies and their substitutes with respect to any other matters as may properly come before the Annual Meeting. Mark each vote with an X in the box.
IF NO DIRECTION IS INDICATED WITH RESPECT TO THE PROPOSALS, THIS PROXY WILL BE VOTED FOR ALL OF KARPUS' NOMINEES AND FOR PROPOSALS 2 AND 3.
This Proxy is valid until the completion of the Annual Meeting. This Proxy will only be valid in connection with Karpus' solicitation of proxies for the Annual Meeting.
IMPORTANT: PLEASE SIGN, DATE AND MAIL THIS PROXY CARD PROMPTLY!
If voting your proxies would, in Karpus' opinion, cause there to be a quorum and the Karpus Nominees and proposals would not be approved, then unless Karpus determines that the Board has agreed to afford shareholders truly independent representation on the Board of the Fund, Karpus may not attend the Annual Meeting, may not vote the undersigned's shares proxy, and the shares may not be counted toward a quorum. If you do not believe the foregoing condition is reasonably specified, or you unconditionally want your shares to be represented at the Annual Meeting, you should not give us your proxy.
KARPUS RECOMMENDS THAT YOU VOTE FOR ALL KARPUS NOMIMNEES, FOR PROPOSAL 2 and FOR PROPOSAL3.
PROPOSAL 1. Election of Trustees - Class III, to serve until 2020 or until their successor has been duly elected and qualified.
[ ] FOR ALL Nominees
[ ] FOR Arthur Charles Regan
[ ] FOR Dr. Daniel Robeson
[ ] WITHHOLD AUTHORITY
[ ] FOR ALL EXCEPT
To withhold authority to vote for certain nominees only, mark "For All Except" and write each such
excepted nominee's name on the line below:
_________________________________________________________
Karpus does not expect that any of the Nominees will be unable to stand for election, but, in the event that any Nominee is unable to serve or for good cause will
not serve, the Shares represented by this proxy card will be voted for substitute nominee(s), to the extent this is not prohibited under MSP's bylaws and
applicable law. In addition, Karpus has reserved the right to nominate substitute person(s) if MSP makes or announces any changes to its bylaws or takes or
announces any other action that has, or if consummated would have, the effect of disqualifying any Nominee, to the extent this is not prohibited under the
bylaws and applicable law. In any such case, Shares represented by this proxy card will be voted for such substitute nominee(s).
Karpus intends to use this proxy to vote "FOR" Messrs. Regan and Robeson. There is no assurance that any of the candidates who have been nominated by MSP
will serve as Trustees if our Nominees are elected.
PROPOSAL 2. Shareholder proposal regarding Termination of the Investment Advisory Agreement
FOR AGAINST ABSTAIN
[ ] [ ] [ ]
PROPOSAL 3. Shareholder proposal regarding a self-tender offer
FOR AGAINST ABSTAIN
[ ] [ ] [ ]
Signature of Stockholder:___________________________________ Signature of Stockholder:_______________________________________
Date: ___________________________________ Date:______________________________________________________
Note: Please sign exactly as your name or names appear on this Proxy and return promptly using the enclosed envelope. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.